Want to see ATYR full AI Analyst Report?
ATYR Stock Chart & Stats
$0.57
-$0.02(-4.98%)
At close: 4:00 PM EDT
$0.57
-$0.02(-4.98%)
Day’s Range― - ―
52-Week Range$0.40 - $6.50
Previous CloseN/A
Volume825.96K
Average Volume (3M)1.96M
Market Cap
$55.91M
Enterprise Value$12.22
Total Cash (Recent Filing)$57.42M
Total Debt (Recent Filing)$11.30M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding98,087,425
10 Day Avg. Volume1,483,218
30 Day Avg. Volume1,963,911
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside426.32% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Global Control Of EfzofitimodRegaining exclusive global rights gives aTyr full control over efzofitimod’s development, regulatory strategy and commercial economics across interstitial lung disease, though it also leaves the company responsible for future funding.
Clinical Activity And Phase 3 PathwayThe therapy’s favorable tolerability and signals across several clinically relevant measures support continued development. A refined Phase 3 design could preserve the program’s option value in underserved pulmonary inflammatory diseases.
Modest Balance-sheet LeverageContained leverage reduces debt-service pressure compared with more highly indebted development-stage companies. This provides some financial flexibility, although declining assets and equity show that losses continue to erode the capital base.
Bears Say
Pre-profit Business ModelaTyr lacks established product sales and remains dependent on clinical success before generating durable operating revenue. Persistent losses limit internal funding capacity and make future progress reliant on financing or partnerships.
Persistent Cash BurnConsistently negative operating and free cash flow indicates that the company cannot currently fund development from operations. Continued clinical investment therefore creates ongoing dependence on external capital, potentially diluting shareholders.
Clinical And Listing Execution RiskThe primary-endpoint miss increases uncertainty around Phase 3 design, regulatory acceptance and eventual efficacy. Separately, unresolved Nasdaq compliance could require a reverse split or create delisting risk, adding execution pressure.
aTyr Pharma News
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $0.40 and its highest was $6.50 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $55.91M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Aug 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.011.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.1.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 98,087,425 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went up 3.327%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (426.32% Upside)
$3.00 (426.32% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 250.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.23%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
ATYR Stock 12 Month Forecast
Average Price Target
$3.00
▲(426.32% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.55% Insiders
26.37% Mutual Funds
2.15% Other Institutional Investors
65.15% Public Companies and
Individual Investors